151 related articles for article (PubMed ID: 12039429)
1. Quantification of the dopaminergic response in Parkinson's disease.
Müller T; Benz S
Parkinsonism Relat Disord; 2002 Jan; 8(3):181-6. PubMed ID: 12039429
[TBL] [Abstract][Full Text] [Related]
2. Correlation between tapping and inserting of pegs in Parkinson's disease.
Müller T; Schäfer S; Kuhn W; Przuntek H
Can J Neurol Sci; 2000 Nov; 27(4):311-5. PubMed ID: 11097522
[TBL] [Abstract][Full Text] [Related]
3. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
4. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
Bachmann CG; Zapf A; Brunner E; Trenkwalder C
Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
[TBL] [Abstract][Full Text] [Related]
6. Delay of simple reaction time after levodopa intake.
Müller T; Benz S; Börnke C
Clin Neurophysiol; 2001 Nov; 112(11):2133-7. PubMed ID: 11682352
[TBL] [Abstract][Full Text] [Related]
7. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
8. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease.
Zach H; Dirkx MF; Roth D; Pasman JW; Bloem BR; Helmich RC
Neurology; 2020 Sep; 95(11):e1461-e1470. PubMed ID: 32651292
[TBL] [Abstract][Full Text] [Related]
9. Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa.
Schaafsma JD; Giladi N; Balash Y; Bartels AL; Gurevich T; Hausdorff JM
J Neurol Sci; 2003 Aug; 212(1-2):47-53. PubMed ID: 12809998
[TBL] [Abstract][Full Text] [Related]
10. Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease.
Contin M; Riva R; Martinelli P; Triggs EJ; Albani F; Baruzzi A
Neurology; 1996 Apr; 46(4):1055-8. PubMed ID: 8780090
[TBL] [Abstract][Full Text] [Related]
11. Comparison of patient rated treatment response with measured improvement in Parkinson's disease.
Davidson MB; McGhee DJ; Counsell CE
J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):1001-5. PubMed ID: 22626942
[TBL] [Abstract][Full Text] [Related]
12. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
13. Integrated robotics platform with haptic control differentiates subjects with Parkinson's disease from controls and quantifies the motor effects of levodopa.
Gaprielian P; Scott SH; Lowrey C; Reid S; Pari G; Levy R
J Neuroeng Rehabil; 2019 Oct; 16(1):124. PubMed ID: 31655612
[TBL] [Abstract][Full Text] [Related]
14. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L
Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic substitution in Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2002 Oct; 3(10):1393-403. PubMed ID: 12387685
[TBL] [Abstract][Full Text] [Related]
16. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
17. Pergolide for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M
Cochrane Database Syst Rev; 2000; (2):CD000235. PubMed ID: 10796704
[TBL] [Abstract][Full Text] [Related]
18. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
19. Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients.
Muller T; Benz S; Przuntek H
Can J Neurol Sci; 2002 Feb; 29(1):73-7. PubMed ID: 11858540
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
